159 related articles for article (PubMed ID: 21572523)
1. Interruption and defaulting of multidrug therapy against leprosy: population-based study in Brazil's Savannah Region.
Heukelbach J; André Chichava O; de Oliveira AR; Häfner K; Walther F; de Alencar CH; Ramos AN; Ferreira AC; Ariza L
PLoS Negl Trop Dis; 2011 May; 5(5):e1031. PubMed ID: 21572523
[TBL] [Abstract][Full Text] [Related]
2. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
Penna GO; Bührer-Sékula S; Kerr LRS; Stefani MMA; Rodrigues LC; de Araújo MG; Ramos AMC; de Andrade ARC; Costa MB; Rosa PS; Gonçalves HS; Cruz R; Barreto ML; Pontes MAA; Penna MLF
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005725. PubMed ID: 28704363
[TBL] [Abstract][Full Text] [Related]
3. Patient profile and treatment satisfaction of Brazilian leprosy patients in a clinical trial of uniform six-month multidrug therapy (U-MDT/CT-BR).
Ferreira IP; Buhrer-Sékula S; De Oliveira MR; Gonçalves Hde S; Pontes MA; Penna ML; Cruz R; Penna GO
Lepr Rev; 2014 Dec; 85(4):267-74. PubMed ID: 25675651
[TBL] [Abstract][Full Text] [Related]
4. Correlates of Defaulting from MDT among Leprosy Patients.
Raju MS; Elkana M; Failbus P; Palla JP; Hembrom UK; Rao PS
Indian J Lepr; 2016 Sep; 87(4):241-248. PubMed ID: 29762953
[TBL] [Abstract][Full Text] [Related]
5. Multidrug Therapy for Leprosy Can Cure Patients with Lobomycosis in Acre State, Brazil: A Proof of Therapy Study.
Gonçalves FG; Rosa PS; de Farias Fernandes Belone A; Carneiro LB; Queiroz de Barros VL; Bispo RF; Alves da Silva Sbardelott Y; Viana Macedo Neves SA; Vittor AY; Woods WJ; Laporta GZ
Am J Trop Med Hyg; 2020 Nov; 104(2):634-639. PubMed ID: 33200722
[TBL] [Abstract][Full Text] [Related]
6.
Hungria EM; Bührer-Sékula S; Oliveira RM; Aderaldo LC; Pontes MAA; Cruz R; de Gonçalves HS; Penna MLF; Penna GO; Stefani MMA
Front Immunol; 2018; 9():915. PubMed ID: 29867930
[TBL] [Abstract][Full Text] [Related]
7. Assessing and improving adherence with multidrug therapy.
Weiand D; Thoulass J; Smith WC
Lepr Rev; 2012 Sep; 83(3):282-91. PubMed ID: 23356029
[TBL] [Abstract][Full Text] [Related]
8. Effect of a conditional cash transfer programme on leprosy treatment adherence and cure in patients from the nationwide 100 Million Brazilian Cohort: a quasi-experimental study.
Pescarini JM; Williamson E; Nery JS; Ramond A; Ichihara MY; Fiaccone RL; Penna MLF; Smeeth L; Rodrigues LC; Penna GO; Brickley EB; Barreto ML
Lancet Infect Dis; 2020 May; 20(5):618-627. PubMed ID: 32066527
[TBL] [Abstract][Full Text] [Related]
9. The impact of multidrug therapy on the epidemiological pattern of leprosy in Juiz de Fora, Brazil.
Soares LS; Moreira Rd; Vilela VV; Alves MJ; Pimentel AF; Ferreira AP; Teixeira HC
Cad Saude Publica; 2000; 16(2):343-50. PubMed ID: 10883033
[TBL] [Abstract][Full Text] [Related]
10. An investigation of attitudes, beliefs and behaviour of leprosy patients, family members and PHC workers towards multidrug therapy in Yangzhou and Dongtai Districts of China.
Chen XS; Ye GY; Jiang C; Li WZ; Bian J; Wang H; Chen W
Lepr Rev; 1997 Jun; 68(2):155-61. PubMed ID: 9217355
[TBL] [Abstract][Full Text] [Related]
11. It is time to review concepts on renal involvement in leprosy: pre- and post-treatment evaluation of 189 patients.
Polito MG; Moreira SR; Nishida SK; Mastroianni Kirsztajn G
Ren Fail; 2015 Aug; 37(7):1171-4. PubMed ID: 26099294
[TBL] [Abstract][Full Text] [Related]
12. Ofloxacin-Containing Multidrug Therapy in Ambulatory Leprosy Patients: A Case Series.
Faust L; Klowak M; MacRae C; Kopalakrishnan S; Showler AJ; Boggild AK
J Cutan Med Surg; 2021; 25(1):45-52. PubMed ID: 32869655
[TBL] [Abstract][Full Text] [Related]
13. Operational barriers to the implementation of multidrug therapy and leprosy elimination in Cameroon.
Nsagha DS; Bamgboye EA; Oyediran AB
Indian J Dermatol Venereol Leprol; 2009; 75(5):469-75. PubMed ID: 19736425
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for physical disability upon release from multidrug therapy in new cases of leprosy at a referral center in Brazil.
Assis BPN; Lyon S; Grossi MAF; Rocha MODC
Rev Inst Med Trop Sao Paulo; 2019 Feb; 61():e13. PubMed ID: 30785567
[TBL] [Abstract][Full Text] [Related]
15. Grade 2 disabilities in leprosy patients from Brazil: Need for follow-up after completion of multidrug therapy.
Raposo MT; Reis MC; Caminha AVQ; Heukelbach J; Parker LA; Pastor-Valero M; Nemes MIB
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006645. PubMed ID: 30011288
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
Pandey A; Uddin MJ; Patel R
Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
[TBL] [Abstract][Full Text] [Related]
17. Multidrug therapy for treatment of paucibacillary leprosy in western Kenya--preliminary communications.
Orege PA; Obura M; Okelo C; Okuku P; Makokha S; Nyawalo J
East Afr Med J; 1990 Sep; 67(9):632-9. PubMed ID: 2253572
[TBL] [Abstract][Full Text] [Related]
18. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.
Kumar A; Girdhar A; Girdhar BK
Indian J Dermatol Venereol Leprol; 2015; 81(4):356-62. PubMed ID: 26144850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
